首页> 外文期刊>Human Gene Therapy >Human Telomerase Reverse Transcriptase Promoter-Driven Oncolytic Adenovirus with E1B-19 kDa and E1B-55 kDa Gene Deletions
【24h】

Human Telomerase Reverse Transcriptase Promoter-Driven Oncolytic Adenovirus with E1B-19 kDa and E1B-55 kDa Gene Deletions

机译:人类端粒酶逆转录酶启动子驱动溶瘤腺病毒与E1B-19 kDa和E1B-55 kDa基因缺失。

获取原文
获取原文并翻译 | 示例
           

摘要

We constructed an oncolytic adenovirus, Adeno-hTERT-E1A, with deletions of the viral E1B, E3A, and E3B regions and insertion of a human telomerase reverse transcriptase (hTERT) promoter-driven early viral 1A (E1A) cassette that confers high transcriptional activity in multiple human tumor cell lines. The oncolytic potential of Adeno-hTERT-E1A was characterized in comparison with that of the E1B-55kDa- and E3B-region-deleted oncolytic adenovirus ONYX-015. Tumor cells infected with Adeno-hTERT-E1A expressed dramatically higher levels of E1A oncoprotein, underwent enhanced lysis, and displayed an earlier and higher apoptotic index than cells infected with ONYX-015. Despite the increase in virus-induced apoptotic death, Adeno-hTERT-E1A replicated and produced functional progeny leading to viral spread, but with reduced efficiency compared with ONYX-015, in particular in A549 cells. Virus-induced E1A expression, host cell apoptosis, viral hexon protein production, and DNA synthesis were markedly reduced in primary human hepatocytes after infection with Adeno-hTERT-E1A as compared with ONYX-015. The strong oncolytic activity of Adeno-hTERT-E1A in tumor cell culture translated into superior antitumor activity in vivo in an MDA-MB-231 solid tumor xenograft model. Adeno-hTERT-E1A thus has strong therapeutic potential and an improved safety profile compared with ONYX-015, which may lead to reduced toxicity in the clinic.
机译:我们构建了溶瘤腺病毒,腺病毒-hTERT-E1A,缺失了病毒E1B,E3A和E3B区,并插入了端粒酶逆转录酶(hTERT)启动子驱动的早期病毒1A(E1A)盒式磁带,赋予了高转录活性在多种人类肿瘤细胞系中与缺失了E1B-55kDa和E3B区的溶瘤腺病毒ONYX-015相比,表征了hTERT-E1A腺癌的溶瘤潜能。与用ONYX-015感染的细胞相比,感染了Adeno-hTERT-E1A的肿瘤细胞表达了更高水平的E1A癌蛋白,细胞裂解得到增强,并且显示出更高的凋亡指数。尽管病毒诱导的细胞凋亡死亡增加,腺病毒-hTERT-E1A复制并产生功能后代,导致病毒扩散,但与ONYX-015相比效率降低,特别是在A549细胞中。与ONYX-015相比,腺病毒-hTERT-E1A感染后,原代人肝细胞中病毒诱导的E1A表达,宿主细胞凋亡,病毒六邻体蛋白生成和DNA合成显着降低。在MDA-MB-231实体肿瘤异种移植模型中,腺病毒-hTERT-E1A在肿瘤细胞培养物中的强溶瘤活性转化为体内优异的抗肿瘤活性。因此,与ONYX-015相比,腺苷-hTERT-E1A具有强大的治疗潜力和更高的安全性,可降低临床毒性。

著录项

  • 来源
    《Human Gene Therapy》 |2008年第12期|p.1383-1400|共18页
  • 作者单位

    Joshua C. Doloff Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, MA 02215.David J. Waxman Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, MA 02215.Youssef Jounaidi Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, MA 02215.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    E1B-19 kDa , E1B-55 kDa , Oncolytic , Adeno-hTERT-E1A;

    机译:E1B-19 kDa;E1B-55 kDa;溶瘤;腺苷-hTERT-E1A;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号